Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADAM BRUFSKY

NPI
1518939537
CMS profile
23688
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$328,723.59

226 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $120,720.13 64
PFIZER INC. $87,228.82 43
Myriad Genetic Laboratories, Inc. $65,287.52 54
AstraZeneca Pharmaceuticals LP $13,333.84 17
AstraZeneca UK Limited $9,777.50 6
GE HEALTHCARE $8,081.36 11
Stemline Therapeutics Inc. $6,089.55 5
PUMA BIOTECHNOLOGY, INC. $4,796.84 7
Eli Lilly and Company $4,200.00 3
Lilly USA, LLC $4,150.54 4
Genentech, Inc. $2,205.52 2
Genentech USA, Inc. $2,203.46 2
Novartis Pharmaceuticals Corporation $257.03 2
Tempus AI, Inc $138.04 2
Menarini Silicon Biosystems, Inc. $129.16 1
Exelixis Inc. $113.10 2
R-Pharm US LLC $11.18 1

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADAM BRUFSKY

NPI 1518939537 · CMS profile ID 23688

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ADAM BRUFSKY, NPI 1518939537, CMS profile ID 23688, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518939537?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

226 matching records · $328,723.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 226 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 226.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myriad Genetic Laboratories, Inc. $6,300.0009/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528422 CMS
Myriad Genetic Laboratories, Inc. $2,100.0009/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528424 CMS
Stemline Therapeutics Inc. $1,170.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142957672 CMS
Myriad Genetic Laboratories, Inc. $700.0009/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528418 CMS
PFIZER INC. $82.1109/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131993019 CMS
Genentech, Inc. $55.5209/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132972321 CMS
Genentech, Inc. $2,150.0009/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132972323 CMS
Stemline Therapeutics Inc. $114.5509/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142957670 CMS
PFIZER INC. $203.7809/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131597874 CMS
PFIZER INC. $369.0009/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131598757 CMS
AstraZeneca Pharmaceuticals LP $95.8509/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533316 CMS
AstraZeneca Pharmaceuticals LP $23.9709/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533008 CMS
AstraZeneca Pharmaceuticals LP $86.4009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110543045 CMS
PFIZER INC. $5,000.0009/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131478351 CMS
AstraZeneca UK Limited $665.0009/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110545067 CMS
Myriad Genetic Laboratories, Inc. $700.0008/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528416 CMS
PFIZER INC. $6,125.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131940597 CMS
PFIZER INC. $644.5408/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131991237 CMS
Myriad Genetic Laboratories, Inc. $513.4507/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528414 CMS
R-Pharm US LLC $11.1807/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1073225610 CMS
Myriad Genetic Laboratories, Inc. $700.0007/28/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528412 CMS
Myriad Genetic Laboratories, Inc. $1,400.0007/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528410 CMS
PFIZER INC. $420.5007/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132036706 CMS
PFIZER INC. $346.6107/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132036708 CMS
GE HEALTHCARE $1,869.0007/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144685222 CMS
GE HEALTHCARE $1,558.0007/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144685224 CMS
Lilly USA, LLC $1,050.0007/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136002789 CMS
Tempus AI, Inc $125.0407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150161717 CMS
Gilead Sciences, Inc. $83.3707/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133861604 CMS
AstraZeneca Pharmaceuticals LP $1,995.0007/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110541293 CMS
Gilead Sciences, Inc. $6,720.0006/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133603238 CMS
Myriad Genetic Laboratories, Inc. $1,400.0006/21/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528408 CMS
AstraZeneca UK Limited $665.0006/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552580 CMS
Gilead Sciences, Inc. $110.7706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133735209 CMS
Gilead Sciences, Inc. $170.5306/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133861598 CMS
Gilead Sciences, Inc. $251.7706/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133861600 CMS
Gilead Sciences, Inc. $480.0206/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133861602 CMS
PFIZER INC. $5,000.0006/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131482601 CMS
PFIZER INC. $5,000.0006/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131483562 CMS
GE HEALTHCARE $593.7706/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144680593 CMS
GE HEALTHCARE $165.3306/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144682814 CMS
GE HEALTHCARE $5.7606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144683102 CMS
PFIZER INC. $3,786.0006/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131528392 CMS
GE HEALTHCARE $312.0006/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144679988 CMS
GE HEALTHCARE $1,869.0006/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144687554 CMS
GE HEALTHCARE $935.0006/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144687556 CMS
AstraZeneca Pharmaceuticals LP $1,995.0006/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533724 CMS
AstraZeneca Pharmaceuticals LP $84.8606/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552532 CMS
Gilead Sciences, Inc. $730.0006/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133598543 CMS
Myriad Genetic Laboratories, Inc. $700.0006/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152528406 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $111,231.40 142
PY2020 $105,073.36 65
PY2021 $98,847.61 69
PY2022 $120,426.69 82
PY2023 $315,034.96 217
PY2024 $328,723.59 226
PY2025 $226,670.49 139

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $22,628.53 17
PY2025 Principal investigator $226,860.66 36
PY2024 Recipient $18,222.75 10
PY2024 Principal investigator $619,403.76 61
PY2023 Recipient $17,617.52 14
PY2023 Principal investigator $617,311.34 66
PY2022 Recipient $18,110.00 11
PY2022 Principal investigator $798,026.53 70
PY2021 Recipient $18,822.84 15
PY2021 Principal investigator $978,981.08 90
PY2020 Recipient $23,428.85 19
PY2020 Principal investigator $671,312.69 76
PY2019 Recipient $14,051.00 2
PY2019 Principal investigator $819,152.37 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,529.76 12/31/2025 Non-covered Recipient Entity
Magee Women's Hospital
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232925791
Principal investigator 1 Genentech, Inc. $3,800.00 12/26/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678953
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $540.00 12/15/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE
ALI-1201 No dispute reported 06/30/2026 1251753700
Recipient F. Hoffmann-La Roche AG $503.68 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211534171
Recipient F. Hoffmann-La Roche AG $292.89 12/12/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211534174
Principal investigator 1 Genentech, Inc. $747.00 12/11/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679809
Principal investigator 1 Genentech, Inc. $4,462.00 11/26/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679811
Recipient PFIZER INC. $3,200.00 11/24/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810901
Principal investigator 1 Daiichi Sankyo Inc. $84.50 11/17/2025 Non-covered Recipient Entity
UPMC Hillman Cancer Center
DS8201-A-U301 No dispute reported 06/30/2026 1223386768
Principal investigator 1 Daiichi Sankyo Inc. $2,782.01 11/07/2025 Non-covered Recipient Entity
UPMC Hillman Cancer Center
DS8201-A-U201 No dispute reported 06/30/2026 1223386766
Principal investigator 1 Daiichi Sankyo Inc. $325.56 11/03/2025 Non-covered Recipient Entity
Edward Hospital
DS8201-A-U305 No dispute reported 06/30/2026 1244555156
Principal investigator 1 Genentech, Inc. $6,840.00 10/21/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211678905
Recipient F. Hoffmann-La Roche AG $1,225.57 10/18/2025 Covered Recipient Physician Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211534168
Recipient Novartis Pharmaceuticals Corporation $665.08 10/10/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291581
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,082.50 10/09/2025 Non-covered Recipient Entity
University Of Pittsburgh
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas No dispute reported 06/30/2026 1235992457
Principal investigator 1 Genentech, Inc. $4,587.00 09/25/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679807
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $30,867.50 07/31/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE
ALI-1201 No dispute reported 06/30/2026 1251753698
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,530.00 07/25/2025 Covered Recipient Teaching Hospital
Upmc - Presbyterian Shadyside
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185537425
Recipient PFIZER INC. $330.00 07/08/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810919
Recipient PFIZER INC. $330.00 07/07/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810895
Recipient PFIZER INC. $3,200.00 06/24/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838536
Principal investigator 1 Daiichi Sankyo Inc. $976.68 06/20/2025 Non-covered Recipient Entity
UPMC Hillman Cancer Center
DS8201-A-U305 No dispute reported 06/30/2026 1223386764
Principal investigator 1 Genentech, Inc. $4,821.25 06/09/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211678903
Recipient PFIZER INC. $3,200.00 06/04/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838125
Recipient PFIZER INC. $3,200.00 06/04/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838134
Principal investigator 1 Genentech, Inc. $747.00 05/29/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679801
Principal investigator 1 Genentech, Inc. $2,047.00 05/15/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679799
Recipient PFIZER INC. $940.00 05/15/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838424
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838611
Principal investigator 1 Genentech, Inc. $3,500.00 05/08/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679805
Principal investigator 1 PFIZER INC. $3,075.00 05/05/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228854734
Principal investigator 1 Genentech, Inc. $248.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678925
Recipient PFIZER INC. $780.00 04/25/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838692
Principal investigator 1 Genentech, Inc. $2,933.00 04/24/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679803
Recipient PFIZER INC. $3,200.00 04/07/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838684
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 03/27/2025 Non-covered Recipient Entity
UPMC Hillman Cancer Center
DS8201-A-U305 No dispute reported 06/30/2026 1223386762
Principal investigator 1 Eli Lilly and Company $3,438.00 03/11/2025 Non-covered Recipient Entity
UNIV OF PITTSBURGH CANCER INSTITUTE CANCER SRVCS
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187891428
Principal investigator 1 Eli Lilly and Company $54.75 02/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187875141
Principal investigator 1 Genentech, Inc. $237.00 02/20/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679793
Principal investigator 1 Genentech, Inc. $1,142.00 02/20/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679797
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,727.73 02/19/2025 Non-covered Recipient Entity
UPMC HILLMAN CANCER CENTER
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185537427
Principal investigator 1 Genentech, Inc. $1,072.00 02/18/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678931
Principal investigator 1 Genentech, Inc. $375.00 02/13/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679795
Recipient PFIZER INC. $330.00 02/10/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838120
Principal investigator 1 Genentech, Inc. $2,550.00 02/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678923
Principal investigator 1 Genentech, Inc. $1,250.00 02/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678927
Principal investigator 1 Genentech, Inc. $1,965.00 02/07/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE CANCER SERVICES
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211678929
Principal investigator 1 Genentech, Inc. $747.00 01/30/2025 Non-covered Recipient Entity
UPMC OSPARS
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679791
Recipient Novartis Pharmaceuticals Corporation $571.31 01/28/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293416
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838700
Principal investigator 1 Eli Lilly and Company $65.80 01/27/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187871285
Principal investigator 1 Eli Lilly and Company $4,011.00 01/07/2025 Covered Recipient Teaching Hospital
UPMC PINNACLE HOSPITALS
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187875359
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,699.62 01/03/2025 Non-covered Recipient Entity
UPMC HILLMAN CANCER CENTER
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185537423